Streetbeat News

SLGC

SomaLogic Inc

somalogic.com

CEO

Adam Taich

Employees

517

Industry

Testing Laboratories

revolutionizing proteomics to transform healthcare somalogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. building on the previous decade of aptamer research, somalogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare. if you would like to learn more about somalogic, contact us at information@somalogic.com or 303-625-9000

Open

2.16

Mkt cap

396M

Volume

34M

High

2.31

P/E Ratio

-3.04

52-wk high

3.79

Low

1.93

Div yield

N/A

52-wk low

1.73

Nautilus Biotechnology has filed a lawsuit in US District Court against SomaLogic and the California Institute of Technology, seeking a declaratory judgment that it does not infringe on any claims of US Patent No. 7,842,793, which is related to DNA origami structures.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 9:23 pm

Madryn Asset Management, holding about 4.2% of SomaLogic's common stock, has issued a letter opposing SomaLogic's proposed merger with Standard BioTools. The opposition from a significant shareholder could influence other investors and potentially affect the merger's progress and SomaLogic's stock price.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:36 pm

Standard BioTools Inc. (LAB) and SomaLogic, Inc. (SLGC) have announced the date for their Special Meetings of Stockholders to vote on their proposed all-stock merger. The meetings are scheduled for January 4, 2024, with stockholders of record as of November 29, 2023, eligible to vote. The merger is expected to close in the first quarter of 2024, pending stockholder approval and other customary closing conditions. Proxy solicitors have been appointed to assist stockholders with voting.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 1:01 pm

The article lists the stocks that gained and lost the most in Thursday's mid-day session. Among the gainers were Intelligent Bio Solutions Inc., Astra Space, Inc., and Tempest Therapeutics, Inc., which saw significant increases due to positive quarterly results and acquisition proposals. Among the losers were Enviva Inc., ContraFect Corporation, and Atara Biotherapeutics, Inc., which saw significant decreases due to poor quarterly results and disappointing clinical trial outcomes.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:13 pm

Several US stocks recorded gains in Thursday's trading session, despite the Dow Jones falling around 75 points. Companies such as Virgin Galactic, Affirm Holdings, Infinera Corporation, Marathon Digital Holdings, SomaLogic, PubMatic, LiveRamp Holdings, Braskem, Calumet Specialty Products Partners, Seritage Growth Properties, Riot Platforms, Duolingo, Bloom Energy Corporation, Vertex, Viasat, Natera, Jackson Financial, Prospect Capital Corporation, Amphastar Pharmaceuticals, Carrols Restaurant Group, MicroStrategy, Coinbase Global, TransDigm Group, Paycor HCM, ACI Worldwide, The Walt Disney Company, Tapestry, and Twilio reported better-than-expected financial results, leading to a surge in their share prices.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 3:14 pm

SomaLogic (NASDAQ:SLGC) reported its Q3 earnings, beating estimated earnings by 29.41% with an EPS of $-0.12 versus an estimate of $-0.17. However, revenue was down $19.66 million from the same period last year. Last quarter, the company beat on EPS by $0.03, which was followed by a 6.4% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 9:35 pm

SomaLogic (NASDAQ:SLGC) reported Q3 losses of $(0.12) per share, beating the analyst consensus estimate of $(0.17) by 29.41%. This is a 33.33% increase over losses from the same period last year. The company also reported quarterly sales of $22.05M, beating the analyst consensus estimate of $20.47M by 7.71%. However, this is a 47.14% decrease over sales from the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 08, 2023 | 9:31 pm

SomaLogic (NASDAQ:SLGC) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.17. The company's past performance shows a pattern of beating EPS estimates, which has often led to an increase in share price. However, the stock has been on a downward trend over the last 52-week period, with shares down 18.96%.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 3:02 pm

SomaLogic has announced its new SomaScan 11K platform. No specific details about the platform or its potential impact on the company's performance were provided in the announcement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:20 pm

During Monday's pre-market session, several healthcare stocks experienced significant movements. LumiraDx, INVO Bioscience, Apollomics, TC BioPharm, AcelRx Pharmaceuticals, and SomaLogic saw increases in their share prices, while Revolution Medicines, Mira Pharmaceuticals, Ambrx Biopharma, Catalyst Biosciences, Outlook Therapeutics, and Biocept saw decreases.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.